Minerva Neurosciences, Inc. Payments of Stock Issuance Costs
Minerva Neurosciences, Inc. (NERV) reported Payments of Stock Issuance Costs of $195.19 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-08-07
- Minerva Neurosciences, Inc. payments of stock issuance costs for the quarter ending 2026-06-30 was $104.32K.
- Minerva Neurosciences, Inc. payments of stock issuance costs for the quarter ending 2026-03-31 was $90.88K.
- Minerva Neurosciences, Inc. payments of stock issuance costs for the quarter ending 2025-12-31 was $5.35M.
- Minerva Neurosciences, Inc. payments of stock issuance costs for the quarter ending 2023-12-31 was $0.00.
- Minerva Neurosciences, Inc. payments of stock issuance costs for fiscal 2025 was $5.39M.
- Minerva Neurosciences, Inc. payments of stock issuance costs for fiscal 2023 was $396.29K.
- Minerva Neurosciences, Inc. payments of stock issuance costs for fiscal 2020 was $455.67K.
- Minerva Neurosciences, Inc. payments of stock issuance costs for fiscal 2017 was $2.94M, a 23.17% decline from fiscal 2016.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $104.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $195.19K 10-Q · filed 2026-08-07 | $5.54M derived: sum of 3 quarters · filed 2026-08-07 | |
| 2026-03-31 | $90.88K 10-Q · filed 2026-05-05 | $5.44M derived: sum of 2 quarters · filed 2026-05-05 | ||
| 2025-12-31 | $5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $5.39M 10-K · filed 2026-03-11 | ||
| 2025-09-30 | $45.17K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $86.69K derived: sum of 2 quarters · filed 2025-02-25 | $396.29K 10-K · filed 2025-02-25 | |
| 2023-09-30 | $86.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $396.29K 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $309.60K 10-Q · filed 2024-08-06 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $236.15K derived: sum of 2 quarters · filed 2022-03-01 | $455.67K 10-K · filed 2022-03-01 | |
| 2020-09-30 | $236.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $455.67K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $219.52K 10-Q · filed 2021-08-02 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $2.90M derived: sum of 2 quarters · filed 2019-03-12 | $2.94M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $2.94M 10-Q · filed 2018-11-05 | ||
| 2017-06-30 | $41.18K 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $156.70K derived: sum of 2 quarters · filed 2018-03-12 | $3.83M 10-K · filed 2018-03-12 | |
| 2016-09-30 | $156.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $3.83M 10-Q · filed 2017-11-06 | ||
| 2016-06-30 | $3.68M 10-Q · filed 2017-08-03 | |||
| 2014-12-31 | $30.25K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | $3.05M derived: sum of 2 quarters · filed 2017-03-13 | $3.05M derived: sum of 3 quarters · filed 2017-03-13 | $3.16M 10-K · filed 2017-03-13 |
| 2014-09-30 | $3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $3.02M derived: sum of 2 quarters · filed 2015-11-05 | $3.13M 10-Q · filed 2015-11-05 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $105.42K 10-Q · filed 2015-08-05 | ||
| 2014-03-31 | $105.42K 10-Q · filed 2015-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |